Abemaciclib + Fulvestrant
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasm
Conditions
Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
Trial Timeline
Jul 23, 2020 → Feb 16, 2022
NCT ID
NCT04305236About Abemaciclib + Fulvestrant
Abemaciclib + Fulvestrant is a phase 2 stage product being developed by Eli Lilly for Breast Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT04305236. Target conditions include Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04305236 | Phase 2 | Terminated |
| NCT01394016 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Neoplasm